Esr1 gene amplification and map3k mutations are selected during adjuvant endocrine therapies in relapsing hormone receptor-positive, her2-negative breast cancer (hr+ her2- bc)

HIGHLIGHTS

• who: Lorenzo Ferrando and colleagues from the University of Milan, Milan, Italy, Department of and Hematology, Fondazione have published the article: ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC), in the Journal: (JOURNAL)
• what: The authors report the results of a retrospective study in which the authors used a customized Next Generation Sequencing (NGS) panel of 134 BC-related genes to investigate the genomic evolution of HR+ HER2- BC in patients treated with adjuvant ET after curative surgery and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.